Monocyte 5-HT1A receptors mediate pindobind suppression of natural killer cell activity

Modulation by catalase

M. G. Frank, Donald R Johnson, S. E. Hendricks, J. L. Wieseler Frank

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Serotonin (5-hydroxytryptamine; 5-HT) modulates constituents of the immune system. 5-HT1A receptor antagonists potently suppress lymphocyte function. NK cell activity (NKCA) was measured after exposure of mononuclear cells to the 5-HT1A receptor antagonist pindobind and the 5-HT1C/2 receptor antagonist ketanserin. Elutriated monocytes were exposed to pindobind, incubated with peripheral blood lymphocytes (PBL) in the presence or absence of an H2O2 scavenger catalase, and NKCA measured. Pindobind, but not ketanserin, suppressed NKCA in vitro. Pindobind-treated monocytes suppressed NKCA, whereas pindobind treatment of PBL did not affect NKCA. Catalase inhibited pindobind-induced suppression of NKCA. These data are consistent with previous results that 5-HT modulates NKCA via 5-HT1A receptors on monocytes and suggest that 5-HT may abrogate monocyte suppression of NKCA by inhibiting monocyte signals such as H2O2.

Original languageEnglish (US)
Pages (from-to)247-253
Number of pages7
JournalInternational Immunopharmacology
Volume1
Issue number2
DOIs
StatePublished - Mar 12 2001

Fingerprint

Receptor, Serotonin, 5-HT1A
Natural Killer Cells
Catalase
Monocytes
Serotonin
Serotonin 5-HT1 Receptor Antagonists
Ketanserin
Lymphocytes
pindobind
Immune System

Keywords

  • 5-HT receptors
  • HO
  • Monocytes
  • NK cells
  • Serotonin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Monocyte 5-HT1A receptors mediate pindobind suppression of natural killer cell activity : Modulation by catalase. / Frank, M. G.; Johnson, Donald R; Hendricks, S. E.; Wieseler Frank, J. L.

In: International Immunopharmacology, Vol. 1, No. 2, 12.03.2001, p. 247-253.

Research output: Contribution to journalArticle

Frank, M. G. ; Johnson, Donald R ; Hendricks, S. E. ; Wieseler Frank, J. L. / Monocyte 5-HT1A receptors mediate pindobind suppression of natural killer cell activity : Modulation by catalase. In: International Immunopharmacology. 2001 ; Vol. 1, No. 2. pp. 247-253.
@article{1ef9293f166a447b88642395fd858151,
title = "Monocyte 5-HT1A receptors mediate pindobind suppression of natural killer cell activity: Modulation by catalase",
abstract = "Serotonin (5-hydroxytryptamine; 5-HT) modulates constituents of the immune system. 5-HT1A receptor antagonists potently suppress lymphocyte function. NK cell activity (NKCA) was measured after exposure of mononuclear cells to the 5-HT1A receptor antagonist pindobind and the 5-HT1C/2 receptor antagonist ketanserin. Elutriated monocytes were exposed to pindobind, incubated with peripheral blood lymphocytes (PBL) in the presence or absence of an H2O2 scavenger catalase, and NKCA measured. Pindobind, but not ketanserin, suppressed NKCA in vitro. Pindobind-treated monocytes suppressed NKCA, whereas pindobind treatment of PBL did not affect NKCA. Catalase inhibited pindobind-induced suppression of NKCA. These data are consistent with previous results that 5-HT modulates NKCA via 5-HT1A receptors on monocytes and suggest that 5-HT may abrogate monocyte suppression of NKCA by inhibiting monocyte signals such as H2O2.",
keywords = "5-HT receptors, HO, Monocytes, NK cells, Serotonin",
author = "Frank, {M. G.} and Johnson, {Donald R} and Hendricks, {S. E.} and {Wieseler Frank}, {J. L.}",
year = "2001",
month = "3",
day = "12",
doi = "10.1016/S1567-5769(00)00015-1",
language = "English (US)",
volume = "1",
pages = "247--253",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Monocyte 5-HT1A receptors mediate pindobind suppression of natural killer cell activity

T2 - Modulation by catalase

AU - Frank, M. G.

AU - Johnson, Donald R

AU - Hendricks, S. E.

AU - Wieseler Frank, J. L.

PY - 2001/3/12

Y1 - 2001/3/12

N2 - Serotonin (5-hydroxytryptamine; 5-HT) modulates constituents of the immune system. 5-HT1A receptor antagonists potently suppress lymphocyte function. NK cell activity (NKCA) was measured after exposure of mononuclear cells to the 5-HT1A receptor antagonist pindobind and the 5-HT1C/2 receptor antagonist ketanserin. Elutriated monocytes were exposed to pindobind, incubated with peripheral blood lymphocytes (PBL) in the presence or absence of an H2O2 scavenger catalase, and NKCA measured. Pindobind, but not ketanserin, suppressed NKCA in vitro. Pindobind-treated monocytes suppressed NKCA, whereas pindobind treatment of PBL did not affect NKCA. Catalase inhibited pindobind-induced suppression of NKCA. These data are consistent with previous results that 5-HT modulates NKCA via 5-HT1A receptors on monocytes and suggest that 5-HT may abrogate monocyte suppression of NKCA by inhibiting monocyte signals such as H2O2.

AB - Serotonin (5-hydroxytryptamine; 5-HT) modulates constituents of the immune system. 5-HT1A receptor antagonists potently suppress lymphocyte function. NK cell activity (NKCA) was measured after exposure of mononuclear cells to the 5-HT1A receptor antagonist pindobind and the 5-HT1C/2 receptor antagonist ketanserin. Elutriated monocytes were exposed to pindobind, incubated with peripheral blood lymphocytes (PBL) in the presence or absence of an H2O2 scavenger catalase, and NKCA measured. Pindobind, but not ketanserin, suppressed NKCA in vitro. Pindobind-treated monocytes suppressed NKCA, whereas pindobind treatment of PBL did not affect NKCA. Catalase inhibited pindobind-induced suppression of NKCA. These data are consistent with previous results that 5-HT modulates NKCA via 5-HT1A receptors on monocytes and suggest that 5-HT may abrogate monocyte suppression of NKCA by inhibiting monocyte signals such as H2O2.

KW - 5-HT receptors

KW - HO

KW - Monocytes

KW - NK cells

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0034745803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034745803&partnerID=8YFLogxK

U2 - 10.1016/S1567-5769(00)00015-1

DO - 10.1016/S1567-5769(00)00015-1

M3 - Article

VL - 1

SP - 247

EP - 253

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 2

ER -